AIM-Harvard/TrialPanorama-filtered huggingface dataset:
Study NCT00513604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: aldesleukin
Description: Given subcutaneously every 8 hours for up to 15 doses, day 0, 720,000 IU/kg
Study NCT00513604 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: therapeutic autologous lymphocytes
Description: Given as infusion, up to 3 x 10\^11 lymphocytes (minimum of 1 x 10\^9), day 0
Study NCT00513604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given intravenously 60 mg/kg/day, day -7 to -6
Study NCT00513604 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Fludarabine phosphate
Description: Given intravenously 25 mg/m\^2/day over 15-30 minutes, day -5 to -1
Study NCT00513604 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Total body irradiation
Description: 600 cGy
Study NCT03231501 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: epitinib succinate
Description: This is a single-arm open label study. A subject would take 160 mg of the study medication (epitinib succinate) every day on a 28-day cycle, until he or she reaches disease progression or intolerability.
Study NCT01739491 — intervention group
Intervention type: DRUG
Intervention: No intervention
Description: This is an obeservational study. Bendamustine hydrochloride will be administered (as per product insert) through intravenous infusion over 30-60 minutes at 100 mg/meter square body surface area on days 1 and 2 of a 28-day cycle.
Study NCT04085965 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Boys and Girls Club summer day camp
Description: Daily camp activities included sports, games, obstacle courses, swimming and boating, summer learning and arts and crafts. Lunch was served daily via the USDA's Summer Food Service Program.
Study NCT03063801 — intervention group
Intervention type: OTHER
Intervention: Data extraction in medical files
Description: Data extraction from medical files, countraverified by the bloodbank database for accuracy.
Study NCT03334136 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 25-Hydroxyvitamin D
Description: Capsules containing 20 000 IU 25-hydroxyvitamin D given orally: five capsules the first day and thereafter one capsule every week for 4 months (average daily dose approximately 3.000 IU)
Study NCT03334136 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo oral capsule
Description: Five capsules the first day and thereafter one capsule every week for 4 months.
Study NCT01870232 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: US guided block
Description: Greater palatine nerve or inferior alveolar nerve blocks will be performed under US guidance
Study NCT02721173 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tazarotene 0.1% gel plus clindamycin 1% gel
Description: Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and tazarotene will be applied 5-10 minutes later.
Study NCT02721173 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Adapalene 0.1% gel plus clindamycin 1% gel
Description: Medications will be advised to apply once daily in the evening after facial cleansing. Clindamycin will be applied first and adapalene will be applied 5-10 minutes later.
Study NCT02822586 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: TSEB Therapy
Description: TSEB is a type of radiation treatment in which the skin over the whole body is treated with electron radiation beams. All participants will receive the same standard TSEB dose and treatment schedule. During TSEB, patients are treated in a standing position on a rotating platform.
Study NCT02822586 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Brentuximab vedotin
Description: An antibody-drug conjugate (ADC) that targets CD30. A standard dose of brentuximab vedotin will be administered to all patients by intravenous infusion 3 weeks prior to initiation of TSEB and then every 3 weeks for 3 cycles.
Study NCT03241303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Acarbose
Description: Glucobay tablets on experimental day.
Study NCT03241303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Oral Tablet
Description: Placebo tablets on experimental day.
Study NCT03241303 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Exendin (9-39)
Description: Infusion of GLP-1 receptor antagonist as a study tool to block GLP-1 activity on experimental day.
Study NCT03241303 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo Saline
Description: 9 mg/ml placebo saline infusion on experimental day.
Study NCT01981772 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 4% lidocaine with 1:100,000 epinephrine
Description: see arm/group description
Study NCT01981772 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 4% buffered lidocaine with 1:100,000 epinephrine
Description: see arm/group description
Study NCT02125747 — intervention group
Intervention type: OTHER
Group type: OTHER
Intervention: No Respiratory Therapy
Description: Patients received conventional treatment.
Study NCT02125747 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Respiratory Therapy
Description: Respiratory Therapy consists of postural drainage, positive expiratory pressure (PEP) and vibropercussion (it is a postural drainage method, which uses chest clapping with a flexible wrist and cupped hands or a mechanical vibrator to loosen and mobilize retained secretions that can then be expectorated or drained). Postural drainage is an airways clearance technique in which patient's body is positioned so that the trachea is inclined downward and below the affected chest area.~The PEP consists of expiratory cycles through a system generating a positive pressure of 10-20 cc (cubic centimeter) water. Vibropercussion is applied by the use of a mechanical system following rib movement during expiration to enhance clearance of secretions.~Intervention group received 30-minute-sessions twice a day, 7 days per week, during hospitalization period.
Study NCT00464009 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Continuing medical education
Description: Group A practices took part in a 90 minute lecture with slides, case-based presentations and discussions of the clinical interventions, instruction in children's dental development, common dental diseases and prevention, screening, referral, counseling and fluoride varnish application. Group B practices received the same as group A and additionally were offered support through telephone conference calls using learning collaborative methods where staff receive ongoing support from CME instructors and learn from one another as they begin to implement systems for preventive care in their practices. The conference calls were moderated by research staff with clinical expertise in primary health care who had assisted in other interventions among NC pediatric and family medicine offices. Group C received the same intervention as Group B and were offered additional in-office support for implementation of preventive dental procedures provided by a dental hygienist.
Study NCT01011387 — intervention group
Intervention type: PROCEDURE
Group type: OTHER
Intervention: NPWT System
Description: Dressing change 3 times per week
Study NCT01011387 — intervention group
Intervention type: DEVICE
Group type: OTHER
Intervention: NPWT system
Description: 3 dressing changes/week for maximum 4 weeks.
Study NCT00950950 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Romosozumab
Description: Administered by subcutaneous injection
Study NCT00950950 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Administered by subcutaneous injection
Study NCT02639598 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Flunarizine
Description: as in arm descriptions
Study NCT02639598 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Topiramate
Description: as in arm descriptions
Study NCT05380778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Deep anesthesia
Description: Drug: High dose propofol, fentanyl and sevoflurane Deep Anesthesia~Other Names:~BIS lower than or equal to 45
Study NCT05380778 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Shallow anesthesia
Description: Drug: Low dose propofol, fentanyl and sevoflurane Shallow Anesthesia~Other Names:~BIS above 45
Study NCT01520220 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2784544
Description: LY2784544 will be taken by mouth per a specified schedule. Each cycle is 28 days.
Study NCT02059785 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Pinocembrin for Injection
Study NCT02059785 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Pinocembrin for Injection
Study NCT02516475 — intervention group
Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: zinc sulfate
Description: 1 zinc sulfate capsule for 15 weeks
Study NCT02516475 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: corn starch
Description: 1 corn starch capsule for 15 weeks
Study NCT01178385 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Cognitive-behavioral therapy
Description: Therapists will work with families for 16 weekly sessions implementing the Behavioral Interventions for Anxiety in Children with Autism (BIACA) CBT program, which is a modified version of a family CBT treatment manual for typically developing children with anxiety disorders. The BIACA intervention program is flexible in nature and employs a modular format. Despite the added flexibility of the modular format, a minimum of three sessions are spent on basic coping skills and eight are spent on in vivo exposure to ensure an adequate and comparable dose of the core elements of CBT for anxiety across cases.
Study NCT01178385 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Treatment as Usual
Description: Participants randomized to this arm will be instructed to continue receiving their prior interventions as recommended by their providers (e.g., psychotherapy, social skills training, behavioral interventions, family participation in family therapy or a parenting class, or pharmacological interventions). Treatment changes (e.g., medication increase, starting psychotherapy in the community) are not prohibited and will be monitored. Thus, treatment will continue as it would in standard practice; and will be monitored through periodic study assessment.
Study NCT02757391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Adoptive Immunotherapy
Description: Undergo CD8 +T cell therapy
Study NCT02757391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Aldesleukin
Description: Given SC
Study NCT02757391 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Cyclophosphamide
Description: Given IV
Study NCT02757391 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Laboratory Biomarker Analysis
Description: Correlative studies
Study NCT02757391 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Pembrolizumab
Description: Given IV
Study NCT03283072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 1
Description: 15 bouts of 2mins:1min hypoxia:hyperoxia
Study NCT03283072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 2
Description: 15 bouts of 1mins:1min hypoxia:hyperoxia
Study NCT03283072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 3
Description: 8 bouts of 2mins:1min hypoxia:hyperoxia
Study NCT03283072 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Intervention 4 (sham)
Description: 15 bouts of 1min:1min normoxia
Study NCT00743834 — intervention group
Intervention type: DRUG
Group type: OTHER
Intervention: Luvox CR
Description: In light of the Luvox-CR dosing procedure of Hollander et al (2003) (50 mg increments weekly) and the available dose capsules of Luvox-CR (100 mg and 150 mg), the Luvox-CR dose will be increased over the first 6 weeks of treatment as tolerated in 50 mg to 100-mg increments every week, as tolerated and clinically indicated, to a bedtime dose between 100 and 300 mg/day. The dose will then be held constant for the duration of the study
Study NCT00743834 — intervention group
Intervention type: BEHAVIORAL
Group type: OTHER
Intervention: Behavioral Therapy
Description: The web-based CBT (CT STEPS) includes an introductory session explaining the treatment, with videotapes of OCD patients who used an earlier version, along with 9 subsequent treatment modules. The CBT will include weekly email feedback from a psychologist in response to questions asked about the CBT by the subjects assigned to this treatment arm.
Study NCT02252666 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neuromodulation Rehabilitation
Description: CN-NINM uses sequenced patterns of electrical stimulation on the tongue. Our hypothesis is that CN-NINM induces neuroplasticity by noninvasive stimulation of two major cranial nerves: trigeminal, CN-V, and facial, CN-VII.
Study NCT03094416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: levothyroxine sodium capsule
Description: after the run-in period, patients will be switched to levothyroxine sodium capsule at the same dose used during run-in
Study NCT03094416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Proton pump inhibitor (PPI)
Description: for the whole study duration all subjects will keep taking their proton pump inhibitor medication, as per prescription and as before inclusion
Study NCT03094416 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Levothyroxine Sodium (LT4) Tablets
Description: during the run-in period, subjects will continue taking their levothyroxine sodium tablet medication as per prescription and as before inclusion
Study NCT01664975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: GDPT regimen
Description: GDPT regimen(Gemcitabine,Cisplatin,Prednisone ,Thalidomide) Cisplatin(DDP) 25 mg/m2,ivgtt（intravenously guttae）,d1-3;Prednisone 60mg/m2,p.o,d1-5;Gemcitabine(GEM) 800mg/m2,ivgtt,30min,d1,8;Thalidomide,p.o,200mg/d,Continued use to the end of chemotherapy .Every 21 days for one cycle and three cycles are required. Efficacy was evaluated every two cycles.
Study NCT01664975 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: CHOP regimen
Description: CHOP regimen(Cyclophosphamide,Vincristine,Doxorubicin,Prednisone) Cyclophosphamide 750mg/d,ivgtt, d1;Vincristine,1.4g/m2,ivgtt, d1;Doxorubicin,50mg/m2,ivgtt,d1;Prednisone 60mg/m2,p.o, d1-5.
Study NCT02874521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-dialytic LF-EMS
Description: Electrical muscle stimulation during haemodialysis
Study NCT02874521 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Intra-dialytic cycle training
Description: Cycle training during haemodialysis
Study NCT00926237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sham rTMS - Sham repetitive transcranial magnetic stimulation
Description: Sham rTMS will be delivered using a commercially available sham coil and targeted to the same brain site in the temporal lobe and in a manner identical to that for active rTMS except that scalp electrodes are used to stimulate the temporalis muscle electrically during sham stimulation to replicate the feel of active TMS.
Study NCT00926237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active 1 Hz rTMS - Active repetitive transcranial magnetic stimulation delivered at 1 Hz frequency
Description: Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 1 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
Study NCT00926237 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active 10 Hz rTMS - active repetitive transcranial magnetic stimulation delivered at 10 Hz frequency
Description: Active rTMS will be targeted either to the mid-superior temporal gyrus opposite the ear with loudest tinnitus or to the same region in the left hemisphere if no asymmetry in tinnitus is present. 10 Hz active rTMS will be delivered at 110% of motor threshold (MT) for a total of 1800 magnetic pulses per session, 4 sessions per week.
Study NCT04115306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: PMD-026
Description: Investigational Drug
Study NCT04115306 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fulvestrant
Description: SERDs
Study NCT01135173 — intervention group
Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: Waterpipe smoking cessation
Description: The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.
Study NCT01135173 — intervention group
Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Waterpipe smoking cessation
Description: The main objective of this study is to compare two levels of intensity of a behavioral intervention for waterpipe smoking cessation, using a randomized controlled trial design. In this trial, brief motivational intervention with self-help materials will be compared with intensive behavioral counseling with four sessions, in order to test the efficacy of each of these interventions. This pilot testing will help us; 1) test the potential efficacy of the developed intervention, 2) fine-tune the intervention in terms of content and format, and 3) assess issues related to recruitment and retention. Thus, feedback from participants and intervention staff will form an essential part of this pilot study to assess the adopted approaches and suggest appropriate modifications.
Study NCT03558711 — intervention group
Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: 18F-PSMA
Description: 18F-PET imaging
Study NCT01736865 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cholecalciferol
Study NCT01736865 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT02279225 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Group Phototherapy
Study NCT02279225 — intervention group
Intervention type: RADIATION
Group type: EXPERIMENTAL
Intervention: Phototherapy + Physical activity
Study NCT02279225 — intervention group
Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Physical activity
Study NCT02279225 — intervention group
Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Study NCT01957449 — intervention group
Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Propranolol
Description: Propranolol by mouth given daily throughout hospitalization for up to 12 months
Study NCT01957449 — intervention group
Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo by mouth given daily throughout hospitalization for up to 12 months.
Study NCT02772406 — intervention group
Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Linked Color Imaging
Study NCT02772406 — intervention group
Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: white light imaging
Study NCT02318316 — intervention group
Intervention type: OTHER
Intervention: Exhaled breath condensate
Description: Breath condensate samples will be collected with a commercially available condenser (EcoScreen®, Erich Jaeger, Germany). Subjects will breathe through a mouthpiece and a two-way non-rebreathing value in which inspiratory and expiratory air were separated, and saliva was trapped. They will be asked to breathe at a normal frequency and tidal volume for 15 minutes while wearing nose clips, allowing collection of 1.5-2.5 mL of condensate. After collecting this, pH will be measured and the waste collection will be stored at -80 degrees. Then 8 isoprostane and nitrotyrosine will be measured collectively
Study NCT05862220 — intervention group
Intervention type: DIAGNOSTIC_TEST
Intervention: D-Dimer vs CTPA
Description: CTPA was performed after performing blood sampling using Siemens Somatom definition AS 24 slice scanners. Non-ionic water-soluble contrast Omnipaque 350 mg I/mg or Visipaque 320 mg I/mg was injected at 4 mm/s maximum dose 100 ml using a Medtron pressure injector.OR, A blood sample was taken before starting the patients on any thrombolytic treatment. The latex agglutination test was used to measure plasma D-dimer level; this was done using a Sysmex CA-7000 automatic coagulation unit. The positivity threshold was above 250 ng/ml.
Study NCT02761330 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketamine
Description: Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
Study NCT02761330 — intervention group
Intervention type: DRUG
Group type: SHAM_COMPARATOR
Intervention: Ketamine
Description: Ketamine will be used to induce general anesthesia with or without subsequent ECT. Within a single patient, the dose will remain consistent throughout the study and is estimated to be 2 mg/kg.
Study NCT02761330 — intervention group
Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Electroconvulsive Therapy
Description: Dose of the ECT charge will be determined during titration session prior to randomization.
Study NCT02761330 — intervention group
Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Electroconvulsive Therapy
Description: Dose of the ECT charge will be determined during titration session prior to randomization.
Study NCT00602602 — intervention group
Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: bevacizumab
Study NCT00602602 — intervention group
Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: fluorouracil